Cloud And Infrastructure Modernization

Service Line: Operations

Finding the right consultant should be this easy.

1

Tell us about your project

2

Interview candidates

(We’ll provide bios within 48 hours on average)

3

Select your consultant and start work!

Find a consultant in our Biotechnology Practice

Prefer email? Write to [email protected]

Capability: Cloud And Infrastructure Modernization

The following discussion illustrates a project that is well suited to the capabilities of an independent consultant in the Umbrex Biotechnology Practice. This is an illustrative example. Umbrex consultants adapt their methodology, timeline, and deliverables to the specific needs of each client.

1) Client Situation

The client operated within the therapeutics-focused biotech ecosystem and required support with Cloud And Infrastructure Modernization in the context of Biotechnology. Leadership across Emerging Therapeutic Biotech (Preclinical), Clinical-Stage Biotech (Phase I–III), Commercial Biotech (Post-Approval), Platform Biotech (Therapeutic Discovery), and Biotech Investors & Incubators asked for a secure, GxP-ready cloud architecture on AWS or Azure with clear network standards, identity, and disaster recovery (DR) that improved agility, reliability, and cost transparency while supporting IND/CTA, PoC, PPQ/CPV, BLA/MAA, and launch readiness. The diagnostic surfaced concrete issues:

  • Fragmented infrastructure and no enterprise landing zone:
    • Workloads resided across on‑prem servers, co‑location facilities, and ad hoc cloud accounts/subscriptions. There was no AWS Control Tower/Azure Landing Zone, no standard VPC/VNet patterns, and inconsistent tagging or guardrails. Shadow IT proliferated for analytics, data science, and collaboration.
  • Identity, access, and SoD inconsistencies:
    • Multiple identity stores (local AD, IdP, SaaS-native) lacked federation and centralized RBAC/ABAC; privileged access and Segregation of Duties (SoD) were not harmonized across ERP, MES, LIMS, QMS, CTMS/EDC, and eTMF. Joiner/mover/leaver controls were manual and lagged.
  • GxP validation and Part 11/Annex 11 posture uneven:
    • Legacy CSV focused on exhaustive low‑risk testing but under‑evidenced critical functions (security, audit trails, record lifecycle). Audit trail review cadence, time synchronization (NTP), e‑signature use, backup/restore verification, and change control evidence varied by system and site.
  • Network and partner connectivity risk:
    • VPN sprawl to CDMOs/CROs without standardized segmentation; no Transit Gateway/Virtual WAN pattern; latency and packet loss impacted MES–LIMS and CTMS–EDC data flows. OT/IT boundaries at plants were blurred; firewalls and micro‑segmentation were inconsistent.
  • Insufficient DR/BCP and ransomware resilience:
    • RTO/RPO targets were undefined or untested; backups existed but immutability (object lock/WORM) and cross‑region replication were absent; DR drills were irregular; runbooks lacked Quality/validation steps for GxP systems.
  • Observability and security monitoring gaps:
    • Logs were scattered (CloudTrail/CloudWatch/GuardDuty not centralized; Azure Activity Logs/Security Center/Defender/Sentinel under‑utilized). No unified SIEM, inconsistent vulnerability management and patching cadence, and limited incident response playbooks tied to Quality/Regulatory escalation.
  • Integration and data lineage pain:
    • File‑based exchanges connected ERP–MES–LIMS–QMS and CTMS–EDC–eTMF; EPCIS (serialization) and E2B (safety) were not regularly verified. There was no governed data platform, catalog, or lineage; FAIR semantics (CDISC, IDMP, OBO/BioPAX) were sporadic.
  • Cost opacity and budget variance:
    • Cloud spend lacked tagging/chargeback/showback; resources were over‑provisioned without autoscaling; dev/test environments lingered; TCO was unclear across infra, SaaS, and services. “Lift‑and‑shift” migrations increased spend without performance gains.
  • Execution friction and validation bottlenecks:
    • No Infrastructure‑as‑Code (IaC) standards (Terraform/CloudFormation/Bicep); environment drift and manual changes slowed validation and audits; dev/QA/prod segregation was ad hoc; change windows conflicted with PPQ/CPV and study milestones.

Indicative KPIs and symptoms included: production uptime below targets for lab and clinical systems; MTTR prolonged due to missing runbooks; failed or skipped DR tests; audit observations referencing audit trail and backup evidence; MES–LIMS data latency impacting batch release; TMF CTA below thresholds; vulnerability remediation exceeding SLAs; and 15–30% month‑over‑month cloud spend variance without FinOps controls. Executives requested a pragmatic, risk‑based modernization program that delivered a secure landing zone, standardized networking and identity, validated controls, robust DR/BCP, and cost transparency—without disrupting GxP operations or critical milestones.

2) Project Objective

The primary objective focused on designing and initiating a secure, GxP‑ready cloud architecture on AWS or Azure—with enterprise landing zone, identity and network standards, disaster recovery and ransomware resilience, observability, and FinOps—that improved agility, reliability, and cost transparency, while enabling faster launch readiness and inspection‑ready evidence.

Secondary objectives included:

  • Standing up a multi‑account/subscription landing zone (AWS Control Tower/Azure Landing Zones) with guardrails, tagging, and IaC.
  • Implementing IAM, SSO (SAML/OIDC), MFA, RBAC/ABAC, SoD, PAM, and joiner/mover/leaver automation across GxP and finance systems.
  • Defining network and partner connectivity patterns (VPC/VNet, Transit Gateway/Virtual WAN, SD‑WAN/SASE, PrivateLink/ExpressRoute/Direct Connect) with micro‑segmentation and OT/IT boundaries.
  • Adopting Computer Software Assurance (CSA) for validation of infrastructure and platform services, anchoring to Part 11/Annex 11 and data integrity (ALCOA+).
  • Establishing DR/BCP with tested RTO/RPO, immutable backups (object lock), cross‑region replication, and validated recovery runbooks.
  • Consolidating logging/monitoring into SIEM (e.g., Sentinel/Splunk) with vulnerability management, patching, and incident response tied to Quality/Regulatory.
  • Deploying FinOps (cost tagging, budgets/alerts, showback/chargeback, rightsizing and scheduling) to stabilize spend and fund growth.
  • Enabling modern compute patterns (EKS/AKS, serverless), integration (iPaaS/APIs), and data platform (catalog/lineage, privacy/tokenization) for CPV and clinical operations analytics.
  • Instituting an operating model (Cloud Center of Excellence/ARB, policy‑as‑code, change control, runbooks) aligned to validation and milestone windows.

3) Methodology and Approach

Workstream 1: Strategy, Current‑State Assessment, and Risk Prioritization

We established the baseline and aligned on risk and milestone priorities.

  • Landscape inventory: accounts/subscriptions, environments, workloads (ERP, MES/eBR, LIMS/CDS, QMS, CTMS/EDC/eTMF, EPCIS, safety/E2B, data science/analytics), integrations, and support models.
  • Compliance and security posture: CSV/CSA artifacts, audit/inspection findings, IAM/SoD, PAM, logging/monitoring, DR/BCP, vulnerability and patch cadence, network diagrams and OT/IT segmentation.
  • Performance/cost: availability and latency metrics, DR test results, cloud bills, tagging coverage, and unit economics. Prioritized remediation linked to IND/PoC/PPQ/BLA/launch gates.

Workstream 2: Landing Zone and Identity Architecture

We created a standardized, enforceable foundation.

  • Landing zone: AWS Control Tower/Azure Landing Zones with multi‑account/subscription hierarchy (security, shared services, dev/test/prod), baseline guardrails (SCPs/Policies), and mandatory tagging (cost center, owner, sensitivity, GxP).
  • Identity: SSO federation, MFA enforcement, RBAC/ABAC role design mapped to GxP/finance SoD; PAM for break‑glass access; automated provisioning (SCIM), leaver workflows, and quarterly access review evidence.
  • Policy as code: baseline controls (CIS/NIST), Config/Policy/Sentinel/OPA, conformance packs, and exception governance with traceable approvals.

Workstream 3: Network, Connectivity, and OT/IT Segmentation

We standardized secure connectivity for plants, partners, and SaaS.

  • Core topology: hub‑and‑spoke (Transit Gateway/Virtual WAN), SD‑WAN/SASE for remote sites, private endpoints (PrivateLink/Service Endpoints), DNS design, and NTP time sync.
  • Partner links: Direct Connect/ExpressRoute for CDMO/CRO; segmentation and micro‑segmentation (security groups/NSGs/NACLs) with least privilege; encrypted site‑to‑site VPN standards and certificate rotation.
  • OT/IT boundaries: firewalls, jump hosts/bastions, historian/SCADA connectivity patterns, and validated data diodes where needed; change windows coordinated with manufacturing validation.

Workstream 4: Security Baseline, Observability, and Incident Response

We raised detection and response to audit‑ready levels.

  • Logging/monitoring: CloudTrail/CloudWatch/GuardDuty/Security Hub on AWS; Azure Activity Logs/Monitor/Defender/Security Center on Azure; centralized SIEM (e.g., Sentinel/Splunk) with correlation rules and retention aligned to GxP.
  • Vulnerability and patching: scanner coverage (agents/appliance), SLA tiers, patch windows coordinated with validation; configuration compliance dashboards.
  • IR runbooks: incident triage, containment, forensics, regulatory/Quality notification triggers, and evidence preservation; tabletop exercises and post‑incident CAPA integration.

Workstream 5: CSA Validation and Data Integrity Controls

We aligned infrastructure controls with Part 11/Annex 11 under CSA.

  • Intended use/critical functions: defined for core services (compute, storage, networking, KMS/Key Vault, secrets, IAM, logging, backup/restore). Focused testing and supplier assurance (SOC 2/ISO 27001).
  • DI controls: audit trail review SOPs (frequency/content/evidence), e‑signature policy linkage, time sync evidence, WORM/immutability (S3 Object Lock/Azure Immutable Blob), backup/restore drill documentation, and periodic review cadence.
  • Validation packages: risk assessments, configuration baselines, test evidence, and inspection storyboards for infra services and platform patterns; change control templates and matrixed responsibilities (IT/Quality).

Workstream 6: DR/BCP, Backup Strategy, and Ransomware Resilience

We made resilience measurable and repeatable.

  • RTO/RPO: set targets by system class (GxP, finance, clinical, manufacturing), mapped to business impact analysis.
  • Backups and replication: policy‑driven snapshots, cross‑region replication, immutability (Object Lock/Immutable Blob), key escrow/rotation, and restore runbooks with Quality verification.
  • DR drills: scheduled game days for priority systems, result logs with issues CAPA’d; failover patterns (pilot light, warm standby, active‑active) by workload criticality.

Workstream 7: Platform Services, Compute Patterns, and Integration

We enabled faster delivery with consistent, validated patterns.

  • Compute: standardized EKS/AKS (container orchestration), serverless (Lambda/Azure Functions), and hardened VM images; golden AMIs/Managed Images, autoscaling, and blue‑green/canary deployment templates.
  • Secrets and keys: AWS KMS/Azure Key Vault integration, HSM where needed, secrets managers (AWS Secrets Manager/Azure Key Vault), rotation policies, and access attestation.
  • Integration: iPaaS/API gateway patterns; event buses/queues (SNS/SQS/EventBridge; Event Grid/Service Bus) for ERP–MES–LIMS–QMS and CTMS–EDC–eTMF flows; EPCIS and E2B connectors with verification jobs.

Workstream 8: Data Platform, Privacy, and Analytics Enablement

We provided governed data for CPV and clinical/operational insights.

  • Lakehouse: data zones (raw/standardized/semantic), catalog and lineage (Glue/AWS DataZone or Purview), access controls, and tokenization/pseudonymization services for HIPAA/GDPR.
  • Data products: CPV datasets (batch parameters, QC/stability), TMF CTA metrics, startup KPIs, program control metrics (SPI/CPI/EAC); KPI dictionary with formulas and sources.
  • MLOps readiness: experiment tracking, model registry, and monitoring for GxP‑adjacent analytics under MRM governance.

Workstream 9: FinOps—Cost Visibility and Optimization

We introduced financial discipline without throttling speed.

  • Tagging and allocation: mandatory cost tags; business unit and program mapping; showback/chargeback reports and budgets/alerts.
  • Optimization: RI/Savings Plans, rightsizing, autoscheduling for dev/test, storage tiering (S3 Glacier/Archive), license optimization; monthly cost reviews with action logs.
  • Dashboards: unit economics (cost per batch/test/site), variance analysis, and forecast tie‑out to FP&A and runway.

Workstream 10: Operating Model, IaC, and Change Management

We institutionalized a sustainable way of working.

  • Cloud Center of Excellence (CCoE) and ARB: decision rights, review gates, and reusable patterns; backlog of platform improvements tied to milestones.
  • IaC and pipelines: Terraform/CloudFormation/Bicep with code review, automated testing, and promotion across dev/QA/prod; change control integrated with Quality for GxP workloads.
  • Runbooks and training: SRE runbooks, playbooks for partner connectivity, DR, and incident response; role‑based training; adoption KPIs and quarterly posture reviews.

4) Data Request

We requested the datasets and artifacts needed to execute cloud and infrastructure modernization across biotech functions and partners. Typical horizons were 12–24 months historical and 12–36 months forward‑looking for milestones and capacity planning.

  • Accounts and workloads:
    • Cloud accounts/subscriptions, resource inventories, environment maps (dev/QA/prod), tagging coverage, ownership lists.
  • Identity and access:
    • IdP configuration (SSO/MFA), RBAC/ABAC role catalogs, SoD matrices, PAM procedures, access review records, joiner/mover/leaver workflows.
  • Network and partner connectivity:
    • VPC/VNet designs, VPN/Direct Connect/ExpressRoute details, firewall rules, OT/IT diagrams, DNS/NTP, latency/throughput metrics.
  • Security and observability:
    • Logging/monitoring configurations (CloudTrail/GuardDuty/Security Hub; Defender/Sentinel), SIEM content, vulnerability scans, patch cadence, IR playbooks, prior incidents and lessons learned.
  • Validation and DI:
    • CSV/CSA risk assessments, intended use/critical function statements, test evidence, audit trail review SOPs and samples, e‑signature policies, time sync/backup/restore evidence, periodic review reports, audit/inspection findings.
  • DR/BCP:
    • RTO/RPO targets, system classifications, backup and replication configs, DR drill reports, runbooks, Quality verification steps.
  • Integration and data:
    • Interface catalogs (ERP–MES–LIMS–QMS; CTMS–EDC–eTMF; EPCIS; E2B), error logs, iPaaS/API gateways; data dictionaries, lineage docs, privacy/tokenization policies.
  • Applications and milestones:
    • System list (ERP, MES/eBR, LIMS/CDS, QMS, CTMS/EDC/eTMF, EPCIS, safety/E2B), version/deployment; PPQ/CPV, filing, study start schedules and blackout windows.
  • Costs and contracts:
    • Cloud bills, tagging/export data, RI/Savings Plans; vendor contracts and SLAs; managed services SOWs; support models and QBR decks.

Common data pitfalls included unknown accounts and orphaned resources, incomplete role catalogs and SoD, untagged spend, undocumented VPNs to partners, missing DR drill evidence, inconsistent audit trail review records, and interface errors without owner or SLA. We established a data dictionary, tag policy, account registry, and version‑controlled repository before design and implementation.

5) Questions for Client

  • Which milestones (IND/CTA, PoC, PPQ/CPV, BLA/MAA, launch) are non‑negotiable in the next 6–18 months, and what infra risks threaten them?
  • What is your preferred cloud stance (AWS, Azure, hybrid) and appetite for managed services (EKS/AKS, serverless, databases) vs. VMs?
  • What RTO/RPO targets apply by system class; when is the next DR drill acceptable; what evidence must Quality review?
  • Which partner links (CDMO/CRO sites) require hardened connectivity (Direct Connect/ExpressRoute) and micro‑segmentation?
  • What IAM/SoD guardrails and audit trail review cadences must be enforced for GxP systems?
  • Where will CSA be applied; what intended use/critical function scope will QA approve for infra/platform validation?
  • Which interfaces must be event‑driven/near real‑time (e.g., MES–LIMS test orders/results; CTMS–eTMF CTA) vs. batch; what iPaaS/API capabilities exist?
  • What FinOps practices do you want (tagging, budgets/alerts, showback/chargeback); what unit economics matter to executives/board?
  • What OT/IT considerations at manufacturing sites constrain network and change windows?
  • Which security controls (SIEM, EDR, vulnerability, PAM) are mandatory; what incident response playbooks and escalation triggers exist?
  • How should the cloud governance model (CCoE/ARB) integrate with Quality change control and program portfolio governance?

6) Interview Guide for Subject Matter Experts

Chief Information Officer / Infrastructure Lead

  • Where do outages and performance issues impact milestones today; which services are most brittle?
  • What architectural principles and standards exist; how is demand prioritized; where does manual work slow delivery?
  • What is the roadmap for decommissioning on‑prem/colo; what constraints exist?

Chief Information Security Officer / Security Operations

  • What is current SIEM coverage and incident response maturity; where are detection gaps?
  • How are privileged access, SoD, and key/secret rotation governed; what audit findings recur?
  • What ransomware and DR/BCP controls are in place; how often do you test?

Quality / CSV–CSA

  • Which infra controls require validation under CSA; what intended use/critical functions must be evidenced?
  • How are audit trail review, time sync, backup/restore artifacts maintained; what inspection questions recur?
  • How should change control integrate with cloud deployments and IaC?

Manufacturing OT / Site IT

  • How are MES/eBR, LIMS, and historians connected; where do latency and outages hit operations?
  • What firewall, zoning, and micro‑segmentation policies exist; when are validation/maintenance windows feasible?

Head of CMC / MSAT

  • Where do infra issues delay method transfer, batch release, or PPQ/CPV analytics; what availability and performance targets are needed?
  • What evidence does QP/RP require for DR and data integrity related to release decisions?

Clinical Systems Owner (CTMS/EDC/eTMF)

  • What startup and CTA metrics depend on integrations; where do failures occur; what SLAs are required?
  • How do privacy/tokenization requirements affect architectures and logs?

Regulatory / Safety

  • What RIMS/publishing constraints and E2B/Safety gateway requirements exist; how should DR/BCP and logs be evidenced for submissions or inspections?

Data & Analytics Lead

  • Which datasets are priority (CPV, TMF CTA, program controls); where does lineage break; what access controls and privacy patterns are needed?
  • What model governance (MRM) is required for validated vs. exploratory analytics?

Finance / FP&A (FinOps)

  • What cost transparency is required; how should unit economics be presented; what showback/chargeback model is acceptable?
  • What budget thresholds and alerts should drive optimization actions?

Vendor Management / Procurement

  • Which MSPs/ISVs are strategic; where can consolidation reduce TCO; what service credits/penalties are realistic?
  • How do QBRs tie to SLA adherence and improvement backlogs?

7) Timeline

We executed a 12–14 week plan with decision gates tailored to Cloud And Infrastructure Modernization within Information Technology.

  • Weeks 1–2: Diagnostic and Principles
    • Inventoried accounts, workloads, IAM, network, security, DR/BCP, validation, costs; mapped milestone dependencies and partner links; prioritized risks.
    • Decision Gate A: Approved architecture principles, CSA scope, tagging policy, and landing zone blueprint.
  • Weeks 3–4: Landing Zone and IAM Design
    • Configured Control Tower/Landing Zones (pilot); defined account/subscription structure, guardrails, tagging; drafted SSO/MFA, RBAC/ABAC, SoD, PAM patterns and joiner/leaver workflows.
    • Decision Gate B: Ratified landing zone design, IAM standards, and policy‑as‑code baseline.
  • Weeks 5–6: Network & Security Baseline
    • Authored hub‑and‑spoke network, partner connectivity, and OT/IT segmentation patterns; deployed logging/monitoring to SIEM; defined vulnerability/patch SLAs and IR playbooks.
    • Decision Gate C: Approved network reference design and security baseline; scheduled interface and DR drills.
  • Weeks 7–8: CSA & DI Controls; DR/BCP Plans
    • Published CSA validation packages for infra services; finalized audit trail review SOPs, backup/restore and immutability standards; set RTO/RPO by system class and DR runbook templates.
    • Decision Gate D: Cleared CSA/DI standards; locked DR/BCP test calendar.
  • Weeks 9–10: Platform Patterns and Data Blueprint
    • Released IaC modules (network, IAM, logging, KMS/Key Vault, EKS/AKS, serverless); drafted integration/iPaaS patterns; defined data platform, catalog/lineage, and privacy/tokenization design.
    • Decision Gate E: Approved platform patterns and data blueprint; prioritized migration candidates.
  • Weeks 11–12: FinOps and Operating Model
    • Implemented tagging, budgets/alerts, rightsizing schedules; built showback; launched CCoE/ARB and change control workflows; issued SRE runbooks and training plan.
    • Decision Gate F: Endorsed FinOps cadence and operating model; agreed wave‑1 migrations and DR drills.
  • Weeks 13–14 (optional): Pilot Execution and Drills
    • Migrated one non‑critical workload with IaC; performed DR drill for a priority GxP system; ran IR tabletop; tuned runbooks and evidence packs; prepared inspection storyboards.

Critical path items included IAM/SoD consensus, partner connectivity and OT/IT segmentation changes, CSA acceptance by Quality, DR drill scheduling around PPQ/clinical windows, SIEM integration, FinOps tagging coverage, and platform pattern adoption by delivery teams.

8) Deliverables

  • Cloud Target Architecture and Landing Zone Pack
    • Reference architecture, multi‑account/subscription hierarchy, guardrails, tagging policy, and policy‑as‑code baseline.
  • Identity & Access Standards
    • SSO/MFA design, RBAC/ABAC role catalogs, SoD matrices for GxP/finance, PAM patterns, access review templates, and automation workflows.
  • Network & Partner Connectivity Blueprint
    • Hub‑and‑spoke, Transit Gateway/Virtual WAN designs, PrivateLink/ExpressRoute/Direct Connect patterns, OT/IT segmentation, DNS/NTP standards, and firewall/micro‑segmentation policies.
  • Security & Observability Baseline
    • SIEM integration runbook, logging/monitoring architecture, vulnerability/patch SLAs, IR playbooks, and escalation ladders tied to Quality/Regulatory.
  • CSA Validation & Data Integrity Package
    • Intended use/critical function inventory for infra; risk assessments and test evidence; audit trail review SOPs; e‑signature/time sync/backup/restore standards; periodic review cadence; inspection storyboards.
  • DR/BCP Strategy and Runbooks
    • System classifications and RTO/RPO targets; immutable backup and replication patterns; DR drill plans and evidence templates; Quality verification steps.
  • Platform Patterns & IaC Library
    • Terraform/CloudFormation/Bicep modules for network, IAM, logging, KMS/Key Vault, EKS/AKS, serverless, and iPaaS connectors; promotion pipelines and guardrails.
  • Data Platform & KPI Dictionary
    • Lakehouse/canonical data model, catalog/lineage (Glue/DataZone or Purview), privacy/tokenization patterns; KPI dictionary for CPV, TMF CTA, startup, and program controls.
  • FinOps Dashboard and Cost Policy
    • Showback/chargeback reports, budgets/alerts, optimization backlog, and unit economics; governance cadence with FP&A.
  • Operating Model & Runbooks
    • CCoE/ARB charters, change control workflows aligned to validation, SRE runbooks, partner connectivity SOPs, DR and IR playbooks; training and adoption plan.
  • Wave‑1 Migration & Drill Report (optional)
    • Pilot migration post‑mortem, DR drill results, CAPA log, and prioritized backlog for scale‑out.

9) Industry Insights

  • CSA is the accelerator for regulated cloud
    • Risk‑based assurance focused on intended use and critical functions delivers faster time‑to‑value than exhaustive CSV—while improving inspection readiness (audit trail, e‑signatures, record lifecycle, change control evidence).
  • Landing zones and policy‑as‑code prevent drift
    • Multi‑account/subscription designs with guardrails, tagging, and IaC keep environments compliant at scale and simplify audits and cost allocation.
  • Zero‑trust and micro‑segmentation protect partner flows
    • Least‑privilege network patterns and PrivateLink/ExpressRoute/Direct Connect with micro‑segmentation reduce risk for CDMO/CRO links and stabilize MES–LIMS and CTMS–EDC exchanges.
  • DR is proven, not declared
    • Immutability, cross‑region replication, and tested runbooks (with Quality verification) are table stakes—especially under ransomware pressure and inspection scrutiny.
  • Observability must tie to Quality and Regulatory
    • SIEM alerts, IR playbooks, and CAPA integration create traceable response; logs and evidence packs should be inspection‑ready and privacy‑aware.
  • FinOps funds science
    • Tagging, budgets/alerts, rightsizing, and showback/chargeback stabilize spend and free budget for PPQ/CPV, trials, and submissions; unit economics support board narratives.
  • OT/IT boundaries matter at PPQ and launch
    • Network, time sync, and change windows at plants must be codified to avoid validation conflicts and production interruptions during PPQ and commercial readiness.
  • What “good” looks like
    • A controlled landing zone; federated identity with SoD and PAM; standardized network and partner connectivity; CSA‑validated infra controls and DI; tested DR/BCP with immutability; centralized SIEM and IR; IaC and reusable platform patterns; governed data platform with lineage; FinOps dashboard and unit economics; and an operating model (CCoE/ARB) aligned to Quality and portfolio governance.
  • Near‑term watch points
    • Vendor API maturity and iPaaS fit; CSA acceptance by QA; partner connectivity changes at CDMOs/CROs; serialization (EPCIS) and safety (E2B) re‑tests; DR drill scheduling around PPQ or pivotal starts; IAM/SoD rollout; and FinOps cultural adoption. Quarterly posture reviews and roadmap refreshes keep modernization aligned with milestones and risk.

Implications for clients we served included enabling Emerging Therapeutic Biotech to deploy a right‑sized, validated cloud foundation before IND/IMPD; supporting Clinical‑Stage Biotech to stabilize MES–LIMS–QMS and CTMS–EDC–eTMF integrations and DR ahead of PoC and PPQ; equipping Commercial Biotech to harden DR/BCP, serialization, and SIEM for launch; guiding Platform Biotech to standardize landing zones, CSA, and FinOps across partnered programs; and providing Biotech Investors & Incubators with diligence views on cloud maturity, compliance posture, and run‑rate cost discipline across portfolios.

Selected Capabilities of our Biotechnology Practice

Strategy & Corporate Development

  • Corporate Strategy And Growth Agenda: Define enterprise ambition, where to play and how to win, therapeutic area focus, build-partner-buy choices, and value creation roadmap for biotech platforms and asset-centric companies.
  • Portfolio Strategy And Indication Prioritization: Optimize pipeline across modalities using rNPV (risk-adjusted net present value), Probability of Technical and Regulatory Success, and constraints to prioritize indications, sequencing, and kill/hold decisions.
  • Business Development And Licensing Strategy: Set business development and licensing (BD&L) strategy, target screening, and out-licensing/in-licensing approach; shape deal thesis, valuation, and term sheets to maximize partnering value and optionality.
  • M&A Strategy And Diligence: Develop biotech mergers and acquisitions (M&A) strategy, longlist, shortlist, and theses; lead commercial, pipeline, and synergy diligence with integration blueprint and carve-out or asset-swap options.
  • Capital Allocation And Investor Readiness: Design capital allocation across programs and platforms; craft investor narrative, valuation, and financing strategy (venture, crossover, IPO) to extend runway and reduce cost of capital.

Operations

  • Manufacturing Operations Excellence: Improve yield, OEE, and right-first-time across upstream, downstream, and fill-finish to cut deviations, cycle time, and cost of goods for biologics and advanced therapies.
  • Tech Transfer And Scale-Up Execution: Plan and execute GMP tech transfer and scale-up, aligning control strategy and PPQ readiness to accelerate time-to-quality and de-risk commercial launch for new modalities.
  • Capacity Modeling And Debottlenecking: Model end-to-end capacity and cycle times, identify bottlenecks, and redesign schedules, changeovers, and cleanroom utilization to unlock throughput and defer capital for biotech facilities.
  • QC Release Cycle Time Reduction: Optimize QC labs with sampling rationalization, Laboratory Information Management System (LIMS), method lifecycle management, and scheduling to shorten batch release times and improve on-time-in-full service.
  • External Manufacturing Performance Management: Set governance with external manufacturing partners, KPIs, escalation, and issue resolution to improve on-time-in-full, right-first-time, and tech transfer outcomes while protecting supply.

Supply Chain

  • Integrated Business Planning And Supply Planning: Build integrated business planning with constrained supply planning and multi‑echelon inventory optimization to improve service, inventory turns, and adherence across drug substance and product networks.
  • Supply Network Design And Footprint Strategy: Optimize network of drug substance and drug product sites, distribution centers, and third‑party logistics to balance total landed cost, service, and risk in make‑buy‑location decisions.
  • Cold Chain And Temperature-Controlled Logistics: Design cold chain strategy, packaging, and lane qualification for 2–8°C, frozen, and cryogenic shipments; enable real‑time monitoring and excursion management to reduce spoilage and write‑offs.
  • Supply Risk And Shortage Management: Build multi‑tier risk mapping, dual‑sourcing strategies, and allocation playbooks with scenario planning and control‑tower alerts to prevent stockouts and manage biologics supply disruptions.
  • Cell And Gene Therapy Orchestration: Design vein‑to‑vein supply chain, chain of identity and custody, apheresis slot scheduling, and courier control to cut turnaround time and failure risk for autologous therapies.

Procurement & Strategic Sourcing

  • Category Strategy And Strategic Sourcing: Build category strategies for GMP raw materials, single-use assemblies, primary packaging; execute e-sourcing and negotiations to deliver Cost of Goods Sold (COGS) reduction and resiliency.
  • CDMO/CRO Vendor Selection And Contracting: Structure sourcing of Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs); set Quality Agreements; negotiate capacity, pricing, and protections to de-risk delivery.
  • Should-Cost Modeling And Clean-Sheet Costing: Develop should-cost models for single-use assemblies, chromatography resins, media, vials, and contract services to set target prices and win fact-based negotiations.
  • Supplier Risk And Continuity Planning: Conduct supplier and tier-2 risk assessments for plasmids, viral vectors, resins; secure long-term agreements, dual-source contracts, and indexation clauses to ensure continuity and price stability.
  • Supplier Relationship Management And Governance: Establish segmentation, joint business plans, Quarterly Business Reviews (QBRs), Key Performance Indicators (KPIs), and innovation pipelines to improve on-time-in-full, quality, and access to new technologies.

R&D & CMC

  • CMC Strategy And IND Readiness: Define phase-appropriate CMC strategy, control plans, and dossier-ready packages to accelerate IND (Investigational New Drug) submissions and de-risk early clinical manufacturing.
  • Process Development And Characterization: Design and optimize upstream and downstream processes using Design of Experiments, scale-down models, and process characterization to achieve titer, purity, and robustness targets pre-transfer.
  • Analytical Development And Method Lifecycle: Build potency, purity, identity, and safety assays; qualify and validate methods; design stability programs to enable release, comparability, and control of critical quality attributes (CQAs).
  • Formulation And Drug Product Development: Develop phase-appropriate formulations, excipient strategies, and container-closure systems for biologics, mRNA, and viral vectors to improve stability, usability, and shelf life.
  • Comparability And Post-Change Strategy: Plan comparability protocols, risk assessments, and bridging analytics for process changes, site moves, or scale-up to protect product quality and avoid clinical rework.

Organization

  • Operating Model And Organizational Design: Design stage-appropriate biotech operating model across R&D, CMC, Clinical, Quality, Supply, and Commercial; align structure, decision rights, and governance to accelerate development and launch.
  • Leadership And Governance Effectiveness: Strengthen executive cadence, board interfaces, decision forums, and RACI (Responsible, Accountable, Consulted, Informed) clarity to speed decisions, resolve cross-functional issues, and drive accountability.
  • Talent Strategy And Workforce Planning: Build capability maps, workforce plans, and location strategy for bioinformatics, process development, regulatory, and commercial roles to meet milestones while optimizing cost and flexibility.
  • Ways Of Working And Agile Implementation: Implement agile teams in R&D and CMC, meeting redesign, OKRs (Objectives and Key Results), and collaboration norms to increase throughput, transparency, and reduce cycle time.
  • Scaling From Virtual To Commercial Organization: Plan build-out of Quality, Supply, and Commercial functions; define roles, spans and layers, and shared services to scale efficiently before first launch.

Marketing

  • Brand Strategy And Positioning: Define biotech brand narrative, target segments, value proposition, and messaging architecture to differentiate in rare and specialty indications and drive HCP and patient preference.
  • Omnichannel HCP Engagement And Content Operations: Design omnichannel journeys, modular content, and channel mix across email, rep-triggered, web, and social to increase HCP reach, engagement, and conversion within regulatory constraints.
  • Key Opinion Leader And Community Influencer Strategy: Map and activate key opinion leaders (KOLs), digital opinion leaders; co-create education, publications, and advisory forums to build credibility and accelerate guideline inclusion and adoption.
  • Launch And Prelaunch Excellence: Build evidence-driven launch plans, disease awareness, patient-finding, and HCP activation; sequence milestones, content, and congresses to maximize share of voice and first-year uptake.
  • Marketing Performance And ROI Analytics: Build dashboards, marketing-mix models, and experimentation to attribute impact, optimize spend, and improve return on investment (ROI) across HCP, patient, and digital channels.

Pricing

  • Launch Pricing And Price Corridor Design: Define Wholesale Acquisition Cost (WAC) and ex-US list prices, price corridors, and price-volume curves by indication to balance access, uptake, and lifetime revenue.
  • Gross-To-Net Optimization: Diagnose rebate, chargeback, copay, 340B Drug Pricing Program (340B), Medicaid Best Price leakages; design contracting, accruals, and governance to improve net price and predictability.
  • Outcomes-Based And Innovative Contracting: Structure outcomes-based contracts, annuity payments, and warranties for gene and cell therapies; define metrics, data flows, and risk-sharing to secure access and net revenue.
  • International Reference Pricing And Launch Sequencing: Model cross-border reference rules, parallel trade, and price spillover; optimize country sequencing, tender posture, and corridors to protect global net price.
  • IRA And Price Renegotiation Readiness: Build Inflation Reduction Act (IRA) strategy, revenue risk scenarios, and negotiation playbooks; adjust contracting, launch timing, and portfolio mix to mitigate price erosion.

Sales

  • Field Force Sizing And Territory Design: Optimize field force size, territories, Customer Relationship Management (CRM) call plans, and routing to maximize healthcare professional (HCP) coverage and productivity for biotech specialty therapeutics.
  • Key Account Management Enablement: Establish Key Account Management (KAM) model for Integrated Delivery Networks (IDNs) and centers of excellence with planning, access pull-through, and cross-functional engagement to drive adoption.
  • Incentive Compensation And Sales Performance Management: Design compliant incentive plans, quotas, and scorecards; align to new patient starts, persistency, and access status to drive specialty biotech revenue growth.
  • Specialty Pharmacy And Hub Pull-Through: Orchestrate specialty pharmacy and patient support hub processes to reduce time-to-fill, improve benefits verification, and increase therapy initiation and adherence for complex treatments.
  • Sales Training And Field Readiness: Develop disease-state and clinical selling curricula, objection handling, and certification; equip field teams with compliant materials and tools to accelerate launch uptake and competitive wins.

Finance

  • FP&A And Runway Management: Build integrated cash, P&L, and scenario models; align to milestones and business development (BD) events; enable rolling forecasts to extend runway and optimize burn.
  • Product Costing And COGS Transparency: Establish standard costing, variance tracking, lot-level analytics, and transfer pricing to improve Cost of Goods Sold (COGS) predictability and margin decisions for biologics.
  • Working Capital Optimization: Optimize inventory policies, supplier terms, and collaboration cash schedules; redesign milestone invoicing to improve cash conversion cycle and fund critical programs.
  • Record To Report And Fast Close: Redesign close processes, chart of accounts, and Sarbanes-Oxley (SOX) controls to enable accurate inventory valuation, capitalization, and fast, audit-ready closes.
  • Collaboration And Revenue Recognition Advisory: Interpret Accounting Standards Codification (ASC) 606 for licenses, milestones, and cost-sharing; design policies, accruals, and systems to ensure compliant, audit-ready biotech revenue recognition and disclosures.

AI, Data & Analytics

  • Biotech Data Platform And Governance: Build FAIR, GxP-compliant data platforms with ontologies and master data to unify preclinical, CMC, clinical, and commercial datasets for analytics, interoperability, and data integrity.
  • CMC Digital Twins And Process AI: Develop bioprocess digital twins, multivariate control, and soft sensors to predict critical quality attributes, boost yield, and reduce deviations, cycle time, and cost.
  • Generative AI Copilots For CMC And Quality: Deploy large language models (LLMs) with Retrieval-Augmented Generation (RAG) for authoring, querying, and change-impact analysis; ensure validation, permissions, and audit trails in regulated environments.
  • RWE And Clinical AI For Trial Acceleration: Build real-world evidence pipelines and machine learning for patient finding, eligibility inference, and site selection to accelerate enrollment and improve protocol feasibility.
  • MLOps And Model Risk Management: Establish data pipelines, feature stores, versioning, monitoring, and validation with model risk controls and change management to safely scale AI in GxP settings.

Transformation

GxP Quality & Compliance

  • Quality Management System Design And Maturity Uplift: Design risk-based QMS aligned to ICH Q10; optimize SOPs, governance, roles, and metrics to meet GMP/GLP/GCP expectations and accelerate approvals and batch release.
  • Inspection Readiness And Remediation: Run risk-based inspection readiness with mock audits, storyboards, SME coaching, and day-in-the-life war rooms; lead remediation and CAPA plans to close FDA/EMA observations.
  • Data Integrity And Computerized Systems Assurance: Assess ALCOA+ data integrity, remediate gaps, and implement risk-based Computer Software Assurance; validate eQMS, LIMS, MES, and analytics with lifecycle controls and audit trails.
  • Deviation CAPA And Change Control Excellence: Redesign deviation, root cause analysis, CAPA effectiveness, and change control workflows; implement analytics and right-first-time behaviors to reduce recurrence, cycle time, and compliance risk.
  • External Partner Quality Oversight And Audits: Establish risk-based oversight for CDMOs, CROs, and suppliers; set Quality Agreements, audit programs, and release-by-exception to strengthen compliance, tech transfer outcomes, and supply reliability.

Program & Portfolio Management

Information Technology

  • IT Strategy And Enterprise Architecture: Define IT strategy, target architecture, and systems roadmap across ERP, MES, LIMS, QMS, CTMS, and EDC to enable scale, compliance, and faster launch readiness.
  • Core Systems Selection And Implementation Readiness: Run vendor selection for ERP, Veeva Vault Quality/Regulatory, MES, LIMS, and CTMS; define requirements, integrations, and implementation governance to de-risk delivery.
  • Cloud And Infrastructure Modernization: Design secure, GxP-ready cloud architecture on AWS or Azure, with network standards and disaster recovery, improving agility, reliability, and cost transparency.
  • Cybersecurity And Identity Management: Build cybersecurity program with risk-based controls, identity and access management, privileged access, and OT segmentation to protect patient data, intellectual property, and manufacturing assets.
  • IT Operating Model And Service Management: Design IT operating model, ITIL processes, and service catalog; establish SLAs, DevSecOps, and vendor management to improve service quality, delivery speed, and compliance.

Regulatory Affairs

  • Global Regulatory Strategy And Agency Engagement: Define IND/CTA-to-BLA/MAA strategy, pursue orphan, Breakthrough Therapy, Regenerative Medicine Advanced Therapy, and PRIME designations, and lead health authority interactions to de-risk development and approvals.
  • Submission Planning And eCTD Readiness: Build submission roadmap, authoring plan, Module 2/3 strategy, vendor/publisher governance, and quality checks to deliver first-cycle, on-time eCTD submissions across regions.
  • Labeling Strategy And Negotiation: Align Target Product Profile, evidence, and claims; lead core data sheet, USPI/SmPC development, negotiation strategies, and CCDS governance to secure competitive labels.
  • Post-Approval Lifecycle And Variations Management: Design regulatory pathways for post-approval changes; prepare supplements and variations, manage commitments, and harmonize dossiers to sustain global compliance and supply continuity.
  • Companion Diagnostic And Combination Product Regulatory Strategy: Define CDx co-development and combination product strategy, classification, and submission pathways; coordinate interactions with FDA device and drug centers to synchronize approvals and enable precision therapy access.

Clinical Development & Operations

  • Protocol Design And Operational Feasibility: Optimize protocol endpoints, eligibility, visit schedules, and assessments using feasibility and real-world data to cut screen failure, patient burden, cost, and cycle time.
  • Country And Site Strategy: Use epidemiology, investigator performance, and startup cycle time data to select countries and sites, set allocations, and build contingency to achieve predictable enrollment.
  • Patient Recruitment And Retention Acceleration: Deploy patient finding, referral networks, decentralized visits, eConsent, diversity plans, and travel support to accelerate enrollment, cut discontinuations, and improve last patient out predictability.
  • Risk Based Quality Management And Monitoring Optimization: Implement risk based quality management per Good Clinical Practice, central monitoring, tolerance limits, and source verification to lower queries, deviations, and monitoring cost.
  • CRO Oversight And Performance Management: Establish sponsor oversight aligned to Good Clinical Practice with KPIs, tolerance limits, issue escalation, and corrective action governance to improve CRO on-time delivery and quality.

Market Access & HEOR

  • Payer Value Proposition And Access Strategy: Define payer value proposition, unmet need, comparators, and access milestones; shape P&T and prior authorization criteria to secure rapid, broad coverage for specialty biologics.
  • Global HTA Strategy And Dossier Development: Develop global value dossier and AMCP dossier; plan NICE, G-BA, SMC, HAS submissions; tailor evidence and narratives to achieve first-cycle HTA approvals.
  • Health Economic Modeling And Evidence Synthesis: Build cost-effectiveness and budget impact models, partitioned survival or Markov; conduct indirect treatment comparisons and network meta-analyses to meet HTA and payer requirements.
  • Real-World Evidence For Value Demonstration: Design RWE strategy including registries, external control arms, and burden-of-illness studies; generate endpoints and PROs supporting HTA, ICER reviews, label expansions, and reimbursement renewals.
  • Coding Coverage And Reimbursement Strategy: Establish coding pathways, HCPCS/CPT/ICD-10 strategies, compendia listings, and site-of-care economics to secure coverage, appropriate payment, and patient affordability across channels.

Connect with the right consultant

Umbrex rapidly connects you with independent professionals who combine top‑tier consulting experience at firms such as McKinsey, Bain, Boston Consulting Group with hands‑on roles.

Find a consultant in our Biotechnology Practice

Prefer email? Write to [email protected]